Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > This company i'm afraid is done

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Aug 04, 2020 8:01pm

175 Views

Post# 31364376

RE:RE:RE:RE:RE:RE:RE:This company i'm afraid is done

Newinvestor68 wrote: Moonshiner I think you need to drop the hootch. This is old news and has nothing to do with R107 because this is a study for inhaled Nitric not the injectable. Hate to be a downer

... in a few short months ... we'll see who will be putting down their hooch

<< Previous

Bullboard Posts

Next >>

Canada Nickel unveils second of seven resources planned by mid-2025